Agios Pharmac (AGIO.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec8

Agios Pharmaceuticals' Pyrukynd Expected to Receive FDA Approval

17:42

Nov19

H.C. Wainwright Analyst Reiterates Buy Rating on Agios Pharma and Sets Target Price

17:54

Agios Announces Topline Results of Mitapivat Phase 3 Trial in Sickle Cell Disease

12:26

Nov13

Agios Pharmaceuticals' Chief Medical Officer Reports Common Stock Disposition

21:10

Oct30

Agios Pharmac released FY2025 Q3 earnings on October 30 Pre-Market EST, actual revenue USD 12.88 M (forecast USD 10.61 M), actual EPS USD -1.7799 (forecast USD -1.8961)

13:30

Agios Pharmaceuticals released FY2025 9 Months earnings on October 30 Pre-Market (EST), actual revenue USD 34.06 M, actual EPS USD -5.2675

13:30

Schedules & Filings

Schedules

Filings

Oct30

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 12.88 M, Net Income -103.43 M, EPS -1.7799

Jul31

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 12.46 M, Net Income -112.02 M, EPS -1.9336

May1

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 8.726 M, Net Income -89.29 M, EPS -1.5539

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change